Hemophilia A (Severe <1%) Medication Savings with TheDrugClub
Last updated
Members can check active-formulary eligibility and membership pricing for Hemophilia A (Severe <1%) medications. A condition association alone does not establish coverage.
What Is Hemophilia A (Severe <1%)?
Hemophilia A (Severe <1%) is a medical condition that may require prescription treatment. Consult a healthcare professional about appropriate options.
Managing Hemophilia A (Severe <1%) with TheDrugClub
Eligible medications linked to the active formulary may have no additional cost under listed supply, quantity, fill, and fulfillment limits. Other prescriptions may qualify for membership pricing. Confirm current terms before filling.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
About Hemophilia A (Severe <1%)
Severe Hemophilia A is a rare, inherited bleeding disorder primarily affecting males. It occurs when the body produces very little or no functional clotting factor VIII, a protein essential for blood to clot properly. Without sufficient factor VIII, even minor injuries or spontaneous events can lead to prolonged bleeding into joints, muscles, or internal organs, causing pain, swelling, and long-term damage, particularly to joints. The "severe" classification indicates that factor VIII activity in the blood is less than 1%, making spontaneous bleeding much more common.
Diagnosis typically involves blood tests to measure clotting factor levels. While there is no cure, effective treatments exist to manage the condition and prevent bleeding episodes.
Common Treatments and Medications
The cornerstone of severe Hemophilia A treatment is factor VIII replacement therapy. This involves infusing concentrated factor VIII, either derived from human plasma or produced synthetically (recombinant factor VIII), directly into a vein. Many patients receive prophylactic treatment, meaning regular infusions (often several times a week) to prevent bleeding before it starts. Others use on-demand treatment, infusing factor VIII when a bleed occurs. While highly effective, these medications are incredibly expensive, often costing hundreds of thousands of dollars per year.
Another important treatment is emicizumab (Hemlibra), a non-factor therapy administered subcutaneously (under the skin) less frequently than factor VIII infusions. It mimics the function of factor VIII and is used for routine prophylaxis in patients with or without factor VIII inhibitors. Gene therapy is an emerging treatment that holds promise for a one-time, lasting solution, but it is still new and carries a significant upfront cost.
How TheDrugClub Helps Members Save
For those managing the high cost of severe Hemophilia A medications, TheDrugClub offers a straightforward solution. For a low monthly membership fee (with a Drug Club membership, members gain access to discounted prices on *all* their prescriptions, including specialty medications like factor VIII concentrates or emicizumab. There are no deductibles, no paperwork, and no complicated
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.